Medication Review: Efficacy & Safety of Risankizumab in Patients with Moderate to Severely Active UC

Thank you to AbbVie for their support of this Medication Review Video Module.In this medication review, Melissa Ferrari, PA, and Jennifer Hamilton, MSPAS, PA-C, provide a comprehensive overview of the INSPIRE and COMMAND clinical trials evaluating risankizumab for the treatment of moderately to severely active ulcerative colitis. The discussion reviews the trial design, patient populations, induction and maintenance dosing strategies, clinical and endoscopic endpoints, and the rationale behind the approved dosing regimen. The presenters also explain the significance of the phase 2 dose-ranging study and how the clinical development program informed the FDA-approved treatment approach.Melissa and Jennifer review key efficacy findings, including clinical remission and endoscopic improvement during both induction and maintenance, with a particular focus on outcomes in advanced therapy-naïve patients. They also discuss practical considerations for selecting between the available maintenance doses, the role of top-down treatment strategies, administration using the on-body injector, and recommendations for patient counseling and liver enzyme monitoring. Safety outcomes are reviewed, reinforcing the established safety profile of risankizumab and providing clinicians with practical guidance for incorporating this IL-23 inhibitor into routine clinical practice.This educational video is designed for gastroenterology nurse practitioners, physician assistants, gastroenterologists, and other healthcare professionals seeking practical insights into evidence-based treatment of ulcerative colitis. Viewers will gain a deeper understanding of the INSPIRE and COMMAND clinical trial data and how these findings can help guide treatment selection, optimize long-term disease control, and support shared decision-making with patients receiving risankizumab.For more GI and hepatology education, visit the GHAPP Digital Hub and the GHAPP ACE app.